PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Older ASCVD patients benefit from LDL-C lowering with evolocumab A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid

Latest News Updates

19th Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 10th October 2023 (Educational supporters)

What do you do after a Statin? So many choices… what is yours?

What do you do after a Statin? So many choices… what is yours?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Anne Goldberg

Posted on 8 February 2024 | Posted by Anne Goldberg | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board, Hot topics

Keynote – HDL and PCSK9: Going for a ride?

Keynote – HDL and PCSK9: Going for a ride?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Manuel Mayr

Posted on 19 October 2023 | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board, Hot topics

PCSK9 targeting: Inside versus outside?

PCSK9 targeting: Inside versus outside?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Corsini

Posted on 19 October 2023 | Posted by Alberto Corsini | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board, Hot topics

Atherogenicity of apoB-containing particles: The Trilogy of LDL, Lp(a) and remnants

Atherogenicity of apoB-containing particles: The Trilogy of LDL, Lp(a) and remnants

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board John Chapman

Posted on 19 October 2023 | Posted by John Chapman | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board

Bempedoic acid: A CLEAR story

Bempedoic acid: A CLEAR story

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Steven Nissen

Posted on 19 October 2023 | Posted by Steve Nissen | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved